These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10026677)

  • 1. Itraconazole and HIV protease inhibitors: an important interaction.
    MacKenzie-Wood AR; Whitfeld MJ; Ray JE
    Med J Aust; 1999 Jan; 170(1):46-7. PubMed ID: 10026677
    [No Abstract]   [Full Text] [Related]  

  • 2. Iatrogenic Cushing syndrome in patients receiving inhaled budesonide and itraconazole or ritonavir: two cases and literature review.
    Blondin MC; Beauregard H; Serri O
    Endocr Pract; 2013; 19(6):e138-41. PubMed ID: 23807527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible fatal interaction between protease inhibitors and methamphetamine.
    Hales G; Roth N; Smith D
    Antivir Ther; 2000 Mar; 5(1):19. PubMed ID: 10846588
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.
    Khaliq Y; Gallicano K; Venance S; Kravcik S; Cameron DW
    Clin Pharmacol Ther; 2000 Dec; 68(6):637-46. PubMed ID: 11180024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arrhythmia risk with saquinavir.
    AIDS Patient Care STDS; 2010 Apr; 24(4):266. PubMed ID: 20402016
    [No Abstract]   [Full Text] [Related]  

  • 6. Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.
    Le Meur L; Tantet C; Lê MP; Desselas E; Bonnal C; Lillo-Le-Louet A; Sonneville R; Massias L; Giraud J; Descamps D; Yazdanpanah Y; Lariven S; Peytavin G
    J Antimicrob Chemother; 2018 Apr; 73(4):1108-1110. PubMed ID: 29294026
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross-toxicity with indinavir.
    Vandercam B; Moreau M; Horsmans C; Gala JL
    Infection; 1998; 26(5):313. PubMed ID: 9795794
    [No Abstract]   [Full Text] [Related]  

  • 8. Roche issues drug interaction warning.
    AIDS Alert; 2005 Apr; 20(4):48. PubMed ID: 15841532
    [No Abstract]   [Full Text] [Related]  

  • 9. Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings.
    Gray A; Abdool Karim SS; Gengiah TN
    AIDS; 2006 Jan; 20(2):302-3. PubMed ID: 16511431
    [No Abstract]   [Full Text] [Related]  

  • 10. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
    Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
    [No Abstract]   [Full Text] [Related]  

  • 11. Fixed drug eruptions to human immunodeficiency virus-1 protease inhibitor.
    Smith KJ; Yeager J; Skelton H
    Cutis; 2000 Jul; 66(1):29-32. PubMed ID: 10916688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro.
    Brilhante RS; Caetano ÉP; Riello GB; Guedes GM; Castelo-Branco Dde S; Fechine MA; Oliveira JS; Camargo ZP; Mesquita JR; Monteiro AJ; Cordeiro Rde A; Rocha MF; Sidrim JJ
    Braz J Infect Dis; 2016; 20(2):155-9. PubMed ID: 26748233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saquinavir: prolongation of PR and QT intervals.
    Prescrire Int; 2011 Jan; 20(112):17. PubMed ID: 21465717
    [No Abstract]   [Full Text] [Related]  

  • 15. Ritonavir and saquinavir combination: 12-week data at ICAAC.
    James JS
    AIDS Treat News; 1996 Oct; (No 256):3. PubMed ID: 11363880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Searching for the right dose of ritonavir-saquinavir.
    TreatmentUpdate; 2001 Sep; 13(5):3. PubMed ID: 11768860
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin system inhibition in a patient having an overdose of HIV protease inhibitor.
    Duval X; Peytavin G; Fouqueray B; Leport C; Vildé JL
    AIDS; 1999 Oct; 13(14):1983-4. PubMed ID: 10513662
    [No Abstract]   [Full Text] [Related]  

  • 19. Decreased methadone effect after ritonavir initiation.
    Geletko SM; Erickson AD
    Pharmacotherapy; 2000 Jan; 20(1):93-4. PubMed ID: 10641980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.
    Lorenzi P; Yerly S; Abderrakim K; Fathi M; Rutschmann OT; von Overbeck J; Leduc D; Perrin L; Hirschel B
    AIDS; 1997 Oct; 11(12):F95-9. PubMed ID: 9342060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.